AGNOS: Open-label Study to Assess the Effect of Ofatumumab 20 mg for Early Relapsing Remitting Multiple Sclerosis st Healthy Controls on Select Outcomes (AGNOS)
An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20 mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes (AGNOS)
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska
Trial Phone: 321.841.1324 ; 321-841-4717
-
IRB No: W22.093.04
Protocol Abbrev: AGNOS
Principal Investigator: Amparo Gutierrez, MD, FAAN
Phase: Drug: Phase IV
Age Group: Adult
Secondary Protocol No: COMB157GUS10
Treatment: 20mg subcutaneous autoinjection of Ofatumumab
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT05084638
-
Objective
To evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease
-
Key Eligibility
RRMS diagnosis, within 6 months of clinically definite MS, and able to use wearable device
